U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07005557) titled 'Chemo-free in Older (>=65) Node-Positive ER+/HER2- Breast Cancer' on May 03.
Brief Summary: This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged >65 years) with lymph node-positive, HR+/HER2- breast cancer.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Adjuvant Therapy
Intervention:
DRUG: Chemotherapy
Chemotherapy options at physician's discretion: TC, EC-T(wP), ...